Revenues from the company's diagnostics business and discovery and analytical solutions business each grew 10 percent on an organic basis.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
The system, called EvolvR, can continuously diversify all nucleotides within a tunable window at user-defined loci using CRISPR-guided nickases.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
The teams, from the Chinese Academy of Sciences and NYU Langone Health, generated viable yeast strains with just one or two chromosomes.
Single-cell RNA sequencing from mouse trachea and human bronchial epithelial cells unearthed new cell types, including ionocytes enriched for CFTR expression.
The grants are designed to help investigators working within groups pursue independent research and advance their careers in genomic science.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
The firm said it will use the funds to build its IP portfolio, expand its team, and develop an infrastructure for partners to build on its CRISPR platform.
Researchers saw subway line-specific microbes on the hands of subway riders, with increased skin microbial community convergence in samples from evening commuters.
Centrillion Technologies received a multimillion US dollar investment from WeDoctor while Centrillion Technologies Taiwan obtained a strategic investment from Arm IoT Fund.
The companies will work on applying barcoding technology to single-cell measurements of gene and protein expression and to immune cell profiling.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The company beat the consensus Wall Street estimate on the top line but missed it on the bottom line. It placed 39 net new ePlex analyzer during the quarter.
Strength in sequencing and array consumables as well as the firm's services drove second quarter revenues to $830 million, easily surpassing analyst estimates.
A panel led by the FH Foundation recommends routine genetic testing for those with very high LDL cholesterol and a family history of high cholesterol or early heart attack.
The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.
With data from more than a million people, researchers found 111 new or known atrial fibrillation-related loci, providing clues to the condition's biology.
The deal comes a little more than month after the companies agreed to form a joint venture that will develop a blockchain-based healthcare service platform.
The Cobas HPV Test is now approved for use as a primary screening test with BD's SurePath and Hologic's ThinPrep PreservCyt Solution.
Last week, GenomeWeb's readers were most interested in Human Longevity's lawsuit against the J. Craig Venter Institute.
Several companies will receive grants to develop hepatitis C molecular point-of-care and core antigen diagnostic assays.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.